



Contact: Rehab AlJamal-Naylor
Tel. 017919-621 733
Email: r.aljamal.naylor@avipero.com

FOR IMMEDIATE PRESS RELEASE

Monday, 6 January 2014.

AVIPERO and Public Health England Announce R&D Collaboration Agreement In Anti-infectives.

EDINBURGH, SCOTLAND-Mon, 6 January, 2014-----The board of AVIPERO (Registered in Scotland SC353945) announced today the formation of joint research and development (R&D) collaboration with Public Health England (PHE) in anti-infectives. The collaboration is effective immediately.

Over the life of the collaboration, PHE and Avipero will jointly establish and collaboratively manage a research program against undisclosed targets that will focus on emerging viral infections.

The Chair of the board of directors of AVIPERO, Prof. Robert J. Naylor, said: “We are excited by our collaboration with our colleagues at PHE and look forward to tangible outcomes for the treatment of emerging viral infections of high unmet medical need. Such direction fits into the ethos of both Avipero and PHE.” Prof Nigel Silman commented: we are delighted to be working with Avipero Ltd. and assisting them by evaluating the efficacy of their innovative anti-viral therapeutic products. The potential to be able to tackle the global disease burden caused by an endemic virus is incredibly exciting, particularly given the severity of this disease.

About AVIPERO Ltd.

AVIPERO Ltd (Registered in Scotland SC353945) is a private biopharmaceutical company established in 2009. Avipero is focused on the development of novel therapeutics for unmet clinical needs, characterised by a loss of cells and tissues. This includes conditions such as Parkinson’s disease (PD), chronic obstructive pulmonary disease (COPD), arthritis and age related cell decline. AVIPERO has a proprietary first-in-class therapeutic platform covered by a strong intellectual property portfolio. Follow us on Twitter @AVIPERO , LinkedIn: <http://www.linkedin.com/company/avipero-ltd> and Facebook: <https://www.facebook.com/pages/Avipero/211039552252904>

About Public Health England

Public Health England’s mission is to protect and improve the nation’s health and to address inequalities through working with national and local government, the NHS, industry and the voluntary and community sector. PHE is an operationally autonomous executive agency of the Department of Health. www.gov.uk/phe Follow us on Twitter @PHE_uk

Forward Looking Statements

Statements contained herein, other than those which are strictly statements of historical fact may include forward-looking information. Such statements will typically contain words such as “believes”, “may”, “plans”, “will”, “estimate”, “continue”, “anticipates”, “intends”, “expects”, and similar expressions. While forward-looking statements represent management’s outlook based on assumptions that management believes are reasonable, forward-looking statements by their nature are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by them. Such factors include, among others, the inherent uncertainty involved in scientific research and drug development, AVIPERO’s early stage of development, lack of product revenues, its additional capital requirements, the risks associated with successful completion of clinical trials and the long lead-times and high costs associated with obtaining regulatory approval to market any product which AVIPERO may develop. Other risk factors include the limited protections afforded by intellectual property rights, rapid technology and product obsolescence in a highly competitive environment and AVIPERO’s dependence on collaborative partners and contract research organizations. These factors should be considered carefully.

Readers are cautioned not to place undue reliance on such forward-looking statements. Similarly, nothing in this press release is meant to promote a pharmaceutical product or make a regulated claim of efficacy.

FOR FURTHER INFORMATION PLEASE CONTACT:

Dr. Rehab AlJamal-Naylor
AVIPERO Ltd
Director and CSO,
+44(0)7919-621-733
info@avipero.com
www.avipero.com

Mr Mitch Rogers
Public Health England
Senior Business Development Manager,
Tel. +44(0)1980612713
mitch.rogers@phe.gov.uk